Content analysis of FDA warning letters to manufacturers of pharmaceuticals and therapeutic biologicals for promotional violations

Drug Information Journal

Volumn 43, Issue 4, 2009, Pages 385-393

  Kamal, Khalid M ^a   Desselle, Shane P ^b   Rane, Pallavi ^a   Parekh, Rachi ^a   Zacker, Christopher ^c  

^a DUQUESNE UNIVERSITY   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF PHARMACY   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Content analysis; Drug promotional claims; FDA; Letter of notice; Violations; Warning letter

Indexed keywords

ARTICLE; CONTENT ANALYSIS; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 68549098030     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150904300401     Document Type: Article

References (17)

1. Center for Drug Evaluation and Research, Division of Drug Marketing, Advertising, and Communications. Laws, regulations, guidances, and enforcement actions. Rockville, MD: US FDA. Available from: http://www.fda.gov/cder/ddmac/ lawsregs.htm. Accessed March 10, 2007.
2. Bramstedt KA. A study of warning letters issued to clinical investigators by the United States Food and Drug Administration. Clin Invest Med. 2004;27(6):316-323. (Pubitemid 40311199)
3. Bramstedt KA, Kassimatis K. A study of warning letters issued to institutional review boards by the United States Food and Drug Administration. Clin Invest Med. 2004;27(3):129-134. (Pubitemid 40311199)
4. Stewart KA, Neumann PJ. FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violation. Value Health. 2002;5(5):390-397.
5. Klaus Krippendorf. Content Analysis: An Introduction to Its Methodology. 2nd ed. Thousand Oaks, CA: Sage; 2004.
6. FDA Warning Letters. Available from: http://www.fda.gov/foi/warning.htm. Accessed March 10, 2007.
7. McGinn T, Wyer PC, Newman TB, Keitz S, Leipzig R, Guyatt G. Tips for learners of evidence-based medicine: 3. Measures of observer variability (kappa statistic). Can Med Assoc J. 2004; 171:1369-1373.
8. Portnoy S. Advertising and promotion of medical devices. J Health Law. 2006; 29(2):265-282.
9. Kaeding P. It's in the mail - responding to an FDA warning letter. Wisconsin Technology Network. Available at: http://wistechnology.com/article. php?id=2117. Accessed October 5, 2007.
10. Mitka M. Report criticizes lack of FDA oversight. JAMA. 2006;296:920-922. (Pubitemid 44285357)
11. Benson EB, Alfors SN. Prescription drug advertising and promotion: learnings from recent Food and Drug Administration warning letters. Drug Inf J. 2007; 41:281-289.
12. Dickinson JG. "Flip the ad" to see proper risk balance, says FDA. Medical Marketing and Media, September 1, 2007.
13. Brown S. Fair balance: legal hassle or competitive edge? DTC Perspectives Magazine. 2004;3(2): 34-36.
14. Holmes ER, Desselle SP. Evaluating the balance of informative and persuasive content within product-specific print DTCs ads. Drug Inf J. 2004;38:83-98.
15. Glinert LH. TV commercials for prescription drugs: a discourse analytic perspective. Res Soc Adm Pharm. 2005;1:158-184.
16. Radensky P. Outcomes research: when can the results be communicated? Drug Benefit Trends. 2000;12(12):49-51.
17. Neumann PJ, Claxton K, Weinstein MC. The FDA's regulation of health economic information: how the Food and Drug Administration could improve the flow of economic information without discouraging research or exposing consumers to risk. Health Aff. 2000;19(5):129-137.